臺灣博碩士論文加值系統

本研究為開發一咪喹莫特 2-甲基-2-丙烯酸-2-（甲氧基乙氧基）乙酯 （MEO2MA）水凝膠敷料，並且探討其抑制蟹足腫細胞增生的效果。我們檢測4種含不同比例交聯劑(二乙二醇二甲基丙烯酸酯（DEGDMA）)的MEO2MA水凝膠，其中以0.2 mol% MEO2MA水凝膠為最佳的咪喹莫特敷料載體材料。MEO2MA水凝膠的最低臨界共溶溫度（LCST），約為24°C，此溫度為水凝膠溶脹和退脹行為的關鍵溫度。同時咪喹莫特的承載和釋放行為，亦是透過水凝膠的溶脹和退脹行為進行。本研究分別探討水凝膠於超純水（Milli-Q water），二甲基甲醯胺（DMF）和磷酸鹽緩衝生理鹽水（PBS）中的溶脹和退脹能力。製作完成的咪喹莫特-MEO2MA水凝膠中，每1mm3 的體積中，咪喹莫特的負載量約27.4 μg。另外，藥物釋放實驗結果指出，於37°C的PBS溶液中，在3天內，咪喹莫特從水凝膠敷料所釋放的量可達總負載量的42.3%。最後於細胞實驗中，蟹足腫成纖維細胞被培養於咪喹莫特-MEO2MA水凝膠樣品上，並且藉由CCK-8法評估蟹足腫成纖維細胞之活性。透過與無含藥之MEO2MA水凝膠樣品比較，咪喹莫特-MEO2MA水凝膠墊於3天內減少了32%的細胞活性。開發的咪喹莫特-MEO2MA水凝膠敷料可以有效抑制蟹足腫成纖維細胞的增殖。因此，咪喹莫特-MEO2MA水凝膠具有極高的潛力應用於治療蟹足腫。

The imiquimod 2-(2-methoxyethoxy) ethyl methacrylate (MEO2MA) hydrogel dressing was developed for the keloid therapy application. Four different di(ethylene glycol) dimethacrylate (DEGDMA) cross-linked amount of MEO2MA hydrogels were characterised and the 0.2 mol% MEO2MA hydrogel was selected as the appropriate imiquimod carrier dressing material. The MEO2MA hydrogel performed a lower critical solution temperature (LCST), which served as a trigger to turn the swelling and deswelling behaviours, at approximately 24°C. The performances of imiquimod loading and releasing were based on the swelling and deswelling properties. The swelling and deswelling ratios were separately measured in Milli-Q water, dimethylformamid (DMF) and phosphate buffered saline (PBS) solutions. The combinative loading procedure was developed to embed the imiquimod into the MEO2MA hydrogel pad. The fabricated imiquimod-MEO2MA hydrogel dressing demonstrated the imiquimod loaded amount reached to about 27.4 μg per 1 mm3 of hydrogel. The released amount of imiquimod from the hydrogel dressing reached to 42.3% of total loaded imiquimod in the PBS solution at 37°C within 3 days. Keloid fibroblasts were cultured on the fabricated imiquimod-MEO2MA pad and CCK-8 assay were applied to evaluate the cell viability of keloid fibroblasts. By comparison with the pure-MEO2MA pad, the imiquimod-MEO2MA pad can reduce cell viability to about 32% in 3 days. Therefore, the developed imiquimod-MEO2MA hydrogel dressing can decrease the proliferation of keloid fibroblasts and has a highly potential to be utilised for the keloid therapy application.

1. Introduction 1
1.1. Background 1
1.1.1 Wound repair mechanisms 1
1.1.2. Keloid 4
1.1.3. Traditional treatment for keloid 6
1.3. Research purpose 8
2. Material and Method 12
2.1. Preparation of MEO2MA hydrogel samples 12
2.2. Preliminary study of MEO2MA hydrogel properties 14
2.2.1 Lower critical solution temperature of MEO2MA hydrogel 15
2.2.2. Characterisation of swelling and deswelling 15
2.2.3. Characterisation of deswelling property 17
2.2.4. Thermal properties 17
2.3 Fabrication of imiquimod-MEO2MA hydrogel 18
2.3.1 Imiquimod loading 19
2.3.2 Study of imiquimod releasing profile 19
2.4. Performance evaluation of fabricated imiquimod-MEO2MA hydrogel 21
3. Result and discussion 23
3.1. Fabricated MEO2MA hydrogels 23
3.2. Characterisations of MEO2MA hydrogel 24
3.2.1. Measurements of the LCST 24
3.2.2. Swelling profiles of the MEO2MA hydrogels 27
3.2.3. Deswelling profiles of the MEO2MA hydrogels 30
3.2.3. Thermal properties 33
3.3. Study of imiquimod loading and releasing 34
3.3.1. Imiquimod loading profile 34
3.3.2. Imiquimod release profile 35
3.4. Characterisation of fabricated imiquimod-MEO2MA hydrogel pad 37
4. Conclusions 39
5. Future Work-Evaluation of hydrogel-fibre composite dressing 41
5.1. Fabrication of the remote-controlled electrospinning machine 42
5.1.1 Mechanical Structure of Electrospinning Machine 42
5.1.2. Remote-Controlled System 44
5.2. Fabrication of Nanofiber Mesh 45
5.2.1. Characterisations of fabricated imiquimod-PCL fibre meshes 45
5.3. Evaluation of hydrogel-fibre composite dressing 48
6. Reference 49
7. Appendix 53
7.1.Conference paper 53

[1] T. K. Hunt, "The physiology of wound healing," Annals of emergency medicine, vol. 17, no. 12, pp. 1265-1273, 1988.
[2]A. J. Whittam et al., "Challenges and Opportunities in Drug Delivery for Wound Healing," Advances in wound care, vol. 5, no. 2, pp. 79-88, 2016.
[3]K. Harding, V. Jones, and P. Price, "Topical treatment: which dressing to choose," Diabetes/metabolism research and reviews, vol. 16, no. S1, pp. S47-S50, 2000.
[4]T. K. Hunt, H. Hopf, and Z. Hussain, "Physiology of wound healing," Advances in skin & wound care, vol. 13, p. 6, 2000.
[5]H. J. Degreef, "How to heal a wound fast," Dermatologic clinics, vol. 16, no. 2, pp. 365-375, 1998.
[6]J. Li, J. Chen, and R. Kirsner, "Pathophysiology of acute wound healing," Clinics in dermatology, vol. 25, no. 1, pp. 9-18, 2007.
[7]S. Ud‐Din and A. Bayat, "Strategic management of keloid disease in ethnic skin: a structured approach supported by the emerging literature," British Journal of Dermatology, vol. 169, no. s3, pp. 71-81, 2013.
[8]吳益嘉 and 湯月碧, "疤痕重整," 臺灣醫學, vol. 9, no. 2, pp. 228-230, 2005.
[9]D. B. Constam, J. Philipp, U. V. Malipiero, P. Ten Dijke, M. Schachner, and A. Fontana, "Differential expression of transforming growth factor-beta 1,-beta 2, and-beta 3 by glioblastoma cells, astrocytes, and microglia," The Journal of Immunology, vol. 148, no. 5, pp. 1404-1410, 1992.
[10]J. P. Andrews, J. Marttala, E. Macarak, J. Rosenbloom, and J. Uitto, "Keloids: The paradigm of skin fibrosis—Pathomechanisms and treatment," Matrix Biology, vol. 51, pp. 37-46, 2016.
[11]K. Froelich, R. Staudenmaier, N. Kleinsasser, and R. Hagen, "Therapy of auricular keloids: review of different treatment modalities and proposal for a therapeutic algorithm," European Archives of Oto-Rhino-Laryngology, vol. 264, no. 12, pp. 1497-1508, 2007.
[12]C. J. Chike-Obi, P. D. Cole, and A. E. Brissett, "Keloids: pathogenesis, clinical features, and management," in Seminars in plastic surgery, 2009, vol. 23, no. 03, pp. 178-184: © Thieme Medical Publishers.
[13]R. Garrett, E. Niiyama, Y. Kotsuchibashi, K. Uto, and M. Ebara, "Biodegradable nanofiber for delivery of immunomodulating agent in the treatment of basal cell carcinoma," Fibers, vol. 3, no. 4, pp. 478-490, 2015.
[14]Z. Zaidi and S. W. Lanigan, "Skin: structure and function," in Dermatology in Clinical Practice: Springer, 2010, pp. 1-15.
[15]M. Jalali and A. Bayat, "Current use of steroids in management of abnormal raised skin scars," The Surgeon, vol. 5, no. 3, pp. 175-180, 2007.
[16]B. Berman and J. Kaufman, "Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids," Journal of the American Academy of Dermatology, vol. 47, no. 4, pp. S209-S211, 2002.
[17]M. Kamperman and A. Synytska, "Switchable adhesion by chemical functionality and topography," Journal of Materials Chemistry, vol. 22, no. 37, pp. 19390-19401, 2012.
[18]H.-Y. Cheung, K.-T. Lau, T.-P. Lu, and D. Hui, "A critical review on polymer-based bio-engineered materials for scaffold development," Composites Part B: Engineering, vol. 38, no. 3, pp. 291-300, 2007/04/01/ 2007.
[19]K. Uhlig et al., "Monitoring cell detachment on PEG-based thermoresponsive surfaces using TIRF microscopy," Soft Matter, vol. 6, no. 17, pp. 4262-4267, 2010.
[20]S. Dhivya, V. V. Padma, and E. Santhini, "Wound dressings-a review," BioMedicine, vol. 5, no. 4, pp. 22-22, 2015.
[21]H. Yin et al., "A bioengineered drug-Eluting scaffold accelerated cutaneous wound healing In diabetic mice," Colloids and Surfaces B: Biointerfaces, vol. 145, pp. 226-231, 2016.
[22]M. Sheridan, L. Shea, M. Peters, and D. Mooney, "Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery," Journal of Controlled Release, vol. 64, no. 1, pp. 91-102, 2000.
[23]A. Jones and D. Vaughan, "Hydrogel dressings in the management of a variety of wound types: A review," Journal of Orthopaedic nursing, vol. 9, pp. S1-S11, 2005.
[24]E. Wischerhoff et al., "Controlled cell adhesion on PEG‐based switchable surfaces," Angewandte Chemie International Edition, vol. 47, no. 30, pp. 5666-5668, 2008.
[25]T. R. Hoare and D. S. Kohane, "Hydrogels in drug delivery: Progress and challenges," Polymer, vol. 49, no. 8, pp. 1993-2007, 2008.
[26]R. París and I. Quijada-Garrido, "Swelling behaviour of thermo-sensitive hydrogels based on oligo (ethylene glycol) methacrylates," European Polymer Journal, vol. 45, no. 12, pp. 3418-3425, 2009.
[27]J. M. García-García, M. Liras, I. Quijada-Garrido, A. Gallardo, and R. París, "Swelling control in thermo-responsive hydrogels based on 2-(2-methoxyethoxy) ethyl methacrylate by crosslinking and copolymerization with N-isopropylacrylamide," Polymer journal, vol. 43, no. 11, pp. 887-892, 2011.
[28]M. E. Ali and A. Lamprecht, "Polyethylene glycol as an alternative polymer solvent for nanoparticle preparation," International journal of pharmaceutics, vol. 456, no. 1, pp. 135-142, 2013.
[29]J. F. Lutz, "Polymerization of oligo (ethylene glycol)(meth) acrylates: toward new generations of smart biocompatible materials," Journal of Polymer Science Part A: Polymer Chemistry, vol. 46, no. 11, pp. 3459-3470, 2008.
[30]W. Yuan, X. Li, S. Gu, A. Cao, and J. Ren, "Amphiphilic chitosan graft copolymer via combination of ROP, ATRP and click chemistry: Synthesis, self-assembly, thermosensitivity, fluorescence, and controlled drug release," Polymer, vol. 52, no. 3, pp. 658-666, 2011.
[31]J.-F. Lutz, K. Weichenhan, Ö. Akdemir, and A. Hoth, "About the phase transitions in aqueous solutions of thermoresponsive copolymers and hydrogels based on 2-(2-methoxyethoxy) ethyl methacrylate and oligo (ethylene glycol) methacrylate," Macromolecules, vol. 40, no. 7, pp. 2503-2508, 2007.
[32]S. G. Roy, A. Kumar, and P. De, "Amino acid containing cross-linked co-polymer gels: pH, thermo and salt responsiveness," Polymer, vol. 85, pp. 1-9, 2016.
[33]M. Xia et al., "A Novel Nanocomposite Hydrogel with Precisely Tunable UCST and LCST," Macromolecular rapid communications, vol. 36, no. 5, pp. 477-482, 2015.
[34]V. H. G. Phan, T. Thambi, M. S. Gil, and D. S. Lee, "Temperature and pH-sensitive injectable hydrogels based on poly(sulfamethazine carbonate urethane) for sustained delivery of cationic proteins," Polymer, vol. 109, pp. 38-48, 2017.
[35]J. Han, K. Wang, D. Yang, and J. Nie, "Photopolymerization of methacrylated chitosan/PNIPAAm hybrid dual-sensitive hydrogels as carrier for drug delivery," International Journal of Biological Macromolecules, vol. 44, no. 3, pp. 229-235, 2009.
[36]M. Liang, T.-M. Yang, H.-P. Chang, and Y.-M. Wang, "Dual-responsive polymer–drug nanoparticles for drug delivery," Reactive and Functional Polymers, vol. 86, pp. 27-36, 2015/01/01/ 2015.
[37]Q. Li et al., "The synthesis and application of heparin-based smart drug carrier," Carbohydrate Polymers, vol. 140, pp. 260-268, 4/20/ 2016.
[38]Č. r. Koňák, B. Ganchev, M. Teodorescu, K. Matyjaszewski, P. Kopečková, and J. Kopeček, "Poly[N-(2-hydroxypropyl)methacrylamide-block-n-butyl acrylate] micelles in water/DMF mixed solvents," Polymer, vol. 43, no. 13, pp. 3735-3741, 2002/06/01/ 2002.
[39]Z.-M. Huang, Y.-Z. Zhang, M. Kotaki, and S. Ramakrishna, "A review on polymer nanofibers by electrospinning and their applications in nanocomposites," Composites science and technology, vol. 63, no. 15, pp. 2223-2253, 2003.
[40]D. H. Reneker and I. Chun, "Nanometre diameter fibres of polymer, produced by electrospinning," Nanotechnology, vol. 7, no. 3, p. 216, 1996.
[41]J. Xie et al., "Nerve guidance conduits based on double-layered scaffolds of electrospun nanofibers for repairing the peripheral nervous system," ACS applied materials & interfaces, vol. 6, no. 12, pp. 9472-9480, 2014.